1. Home
  2. LGI vs TVRD Comparison

LGI vs TVRD Comparison

Compare LGI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGI
  • TVRD
  • Stock Information
  • Founded
  • LGI 2004
  • TVRD 2017
  • Country
  • LGI United States
  • TVRD United States
  • Employees
  • LGI N/A
  • TVRD N/A
  • Industry
  • LGI
  • TVRD Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGI
  • TVRD Health Care
  • Exchange
  • LGI Nasdaq
  • TVRD Nasdaq
  • Market Cap
  • LGI 189.3M
  • TVRD 166.5M
  • IPO Year
  • LGI N/A
  • TVRD N/A
  • Fundamental
  • Price
  • LGI $15.52
  • TVRD $25.61
  • Analyst Decision
  • LGI
  • TVRD Strong Buy
  • Analyst Count
  • LGI 0
  • TVRD 1
  • Target Price
  • LGI N/A
  • TVRD $39.00
  • AVG Volume (30 Days)
  • LGI 41.1K
  • TVRD 39.1K
  • Earning Date
  • LGI 01-01-0001
  • TVRD 05-21-2025
  • Dividend Yield
  • LGI 7.10%
  • TVRD N/A
  • EPS Growth
  • LGI N/A
  • TVRD N/A
  • EPS
  • LGI N/A
  • TVRD N/A
  • Revenue
  • LGI N/A
  • TVRD N/A
  • Revenue This Year
  • LGI N/A
  • TVRD N/A
  • Revenue Next Year
  • LGI N/A
  • TVRD N/A
  • P/E Ratio
  • LGI N/A
  • TVRD N/A
  • Revenue Growth
  • LGI N/A
  • TVRD N/A
  • 52 Week Low
  • LGI $12.66
  • TVRD $8.14
  • 52 Week High
  • LGI $16.68
  • TVRD $31.32
  • Technical
  • Relative Strength Index (RSI)
  • LGI 57.99
  • TVRD N/A
  • Support Level
  • LGI $15.34
  • TVRD N/A
  • Resistance Level
  • LGI $15.68
  • TVRD N/A
  • Average True Range (ATR)
  • LGI 0.25
  • TVRD 0.00
  • MACD
  • LGI 0.12
  • TVRD 0.00
  • Stochastic Oscillator
  • LGI 90.12
  • TVRD 0.00

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: